Telligen’s Quality Improvement Workbook is designed to provide your team with the tools and resources needed to successfully implement quality improvement initiatives within your organization. By following the timeline, using the goal statement template, and tracking progress, you can ensure that your efforts are effective and that meaningful progress is made towards your goals.

Buprenorphine for Pain: A Transition Guide from Full Agonist Opioid Prescriptions is a tool intended to aid clinicians in switching patients off of full opioid agonists to buprenorphine, a partial mixed opioid agonist for pain management.

The Buprenorphine Resource Guide is a resource that contains the various FDA-approved formulations of buprenorphine for Opioid Use Disorder and pain management. This resource guide also includes a brief history of buprenorphine and explains its analgesic effects.

The Quality Improvement Organization (QIO) Program 2021 Yearly Summary demonstrates how QIO Program initiatives support providers and local and tribal communities to improve health care quality, access, value and equity for people with Medicare. It provides a snapshot of the people, stories and data behind another year of challenges - and successes - in health care quality. 

Since 1978 AAGP has been working to improve the lives of our members’ patients, their families, train the next generation of geriatric mental health clinicians, and advance the research agenda for the mental health of older people.

The report “Dementia: a public health priority” has been jointly developed by WHO and Alzheimer's Disease International. The purpose of this report is to raise awareness of dementia as a public health priority, to articulate a public health approach and to advocate for action at international and national levels.

Antipsychotic medications are commonly used to manage the behavioral and psychological symptoms of dementia. Several large studies have demonstrated an association between treatment with antipsychotics and increased morbidity and mortality in people with dementia.

Antipsychotics medications are approved by the U.S. Food and Drug Administration (FDA) for treatment of schizophrenia and bipolar disorder. These medications are commonly divided into two classes, reflecting two waves of historical development: the conventional antipsychotics and the atypical. The conventional antipsychotics served as the first successful pharmacologic treatment for primary psychotic disorders such as schizophrenia.